| Literature DB >> 36254028 |
Jian Wang1, Zhe-Xiang Feng2, Tao Ren2, Wei-Yu Meng1, Imran Khan1, Xing-Xing Fan1, Hu-Dan Pan3, Liang Liu3, Yi-Jun Tang2, Xiao-Jun Yao1, Run-Ze Li3, Mei-Fang Wang2, Elaine Lai-Han Leung2,4,5.
Abstract
Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentiating TB from a malignant tumor. A total of 815 patients who were diagnosed with TB or cancer in Hubei Shiyan Taihe Hospital from 2014 to 2017 were collected. Amongst them, 717 were found to have PE by thoracoscopy. Clinical characteristics, patients' blood parameters and PE indicator information were summarized for analysis. Patients with MPE had higher percentages to be bloody and negative of Rivalta test in PE than those with TPE. For clinical indicators, comparison of the specific parameters in blood showed that 18 indicators were higher in the TPE group than in the MPE group. By contrast, 12 indicators were higher in the MPE group than in the TPE group (P < .01). In addition, in PE tests, 3 parameters were higher in the TPE group, whereas other 4 parameters were higher in the MPE group (P < .01). Then, for clinical diagnosing practice, ROC analysis and principal component analysis were applied. The top 6 relevant indicators with area under curve over 0.70 were screened out as follows: hydrothorax adenosine dehydrogenase (pADA, 0.90), hydrothorax high-sensitivity C reactive protein (0.79), percentage of blood monocyte (sMONp, 0.75), blood high-sensitivity C reactive protein (sHsCRP, 0.73), erythrocyte sedimentation rate (0.71) and blood D-dimer (0.70). Moreover, logistic regression model revealed that a specific combination of 3 biomarkers, namely, pADA, sMONp and sHsCRP, could enhance the distinguishment of TB from malignant tumor with PE (area under curve = 0.944, 95% confidence interval = 0.925-0.964). The diagnostic function of the top single marker pADA in patients from different groups was analyzed and it was found to maintain high specificity and sensitivity. The 6 indicators, namely, pADA, hydrothorax high-sensitivity C reactive protein, sMONp, sHsCRP, sESR and blood D-dimer, showed significant diagnostic value for clinicians. Further, the combination of pADA, sMONp and sHsCRP has high accuracy for differential diagnosis for the first time. Most interestingly, the single marker pADA maintained high specificity and sensitivity in patients with different statuses and thus has great value for rapid and accurate diagnosis of suspected cases.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36254028 PMCID: PMC9575824 DOI: 10.1097/MD.0000000000031027
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Age and gender characteristics of the study population.
| Features | Clinical diagnosis | F/X2 | ||
|---|---|---|---|---|
| Tuberculosis | Cancer | Total | ||
| Total | 641 | 174 | 815 | |
| With PE | 570 | 147 | 717 | |
| Without PE | 71 | 27 | 98 | |
| Gender | ||||
| Male | 453 | 92 | 545 | 19.57 |
| Female | 188 | 82 | 270 | .0001 |
| Age | ||||
| <25 | 149 | 1 | 150 | |
| 25 to 45 | 245 | 15 | 260 | 162.18 |
| 45 to 65 | 191 | 102 | 293 | .0001 |
| >65 | 56 | 56 | 112 | |
PE = pleural effusion.
Demographic and clinical characteristics of the study population.
| Features | Clinical diagnosis | F/X2 | ||
|---|---|---|---|---|
| Tuberculosis | Cancer | Total | ||
|
| 641 | 174 | 815 | |
| Yes | 570 (88.9%) | 147 (84.5%) | 717 | 2.551 |
| No | 71 (11.1%) | 27 (15.5%) | 98 | .11 |
|
| 570 | 147 | 717 | |
| Yes | 346 (60.7%) | 18 (12.2%) | 364 | 109.79 |
| No | 224 (39.3%) | 129 (87.8%) | 353 | .0001 |
|
| 560 | 145 | 705 (12 missed) | |
| Yellow | 471 (84.1%) | 79 (54.5%) | 550 | 73.21 |
| Pink | 30 (5.4%) | 8 (5.5%) | 38 | .0001 |
| Red | 59 (10.5%) | 58 (40.0%) | 117 | |
|
| 569 | 147 | 716 (1 missed) | |
| Turbid | 270 (47.5%) | 99 (67.3%) | 550 | 18.52 |
| Light turbid | 182 (32.0%) | 29 (19.7%) | 38 | .0001 |
| Transparent | 117 (20.6%) | 19 (12.9%) | 117 | |
|
| 570 | 146 | 716(1 missed) | |
| Negative | 48 (8.4%) | 25 (17.1%) | 73 | 9.61 |
| Positive | 522 (91.6%) | 121 (82.9%) | 643 | .002 |
Figure 1.Patients with TB and CA were grouped by unsupervised hierarchical clustering of blood and pleural effusion clinical indicators. CA= tumor, TB = tuberculosis.
Summary of indicators from comparative analysis of serum and pleural effusion.
| Indicators | Diagnosis | N | Mean | SEM | Mann–Whitney |
|---|---|---|---|---|---|
| pCell | TB | 567 | 19858.46 | 3463.52 | <0.001 |
| CA | 144 | 59114.03 | 11069.29 | ||
| pMON | TB | 563 | 79.66 | 0.94 | <0.001 |
| CA | 147 | 75.33 | 1.74 | ||
| pTP | TB | 547 | 47.99 | 0.79 | <0.001 |
| CA | 142 | 50.44 | 6.93 | ||
| pGLU | TB | 548 | 5.05 | 0.16 | 0.001 |
| CA | 142 | 5.59 | 0.26 | ||
| pAMS | TB | 546 | 40.73 | 1.02 | <0.001 |
| CA | 142 | 345.85 | 79.17 | ||
| pHsCRP | TB | 548 | 24.63 | 1.16 | <0.001 |
| CA | 142 | 8.07 | 0.87 | ||
| pADA | TB | 547 | 44.27 | 1.00 | <0.001 |
| CA | 141 | 11.90 | 0.97 | ||
| sPTA | TB | 450 | 102.62 | 4.66 | <0.001 |
| CA | 121 | 114.07 | 8.63 | ||
| sPT | TB | 537 | 13.19 | 1.31 | <0.001 |
| CA | 151 | 11.78 | 0.66 | ||
| sPTR | TB | 523 | 1.46 | 0.38 | <0.001 |
| CA | 146 | 0.99 | 0.01 | ||
| sINR | TB | 537 | 1.72 | 0.36 | <0.001 |
| CA | 151 | 1.26 | 0.24 | ||
| sAPTT | TB | 537 | 31.81 | 0.25 | 0.013 |
| CA | 152 | 30.95 | 0.53 | ||
| sFbg | TB | 537 | 5.44 | 0.08 | <0.001 |
| CA | 152 | 4.77 | 0.14 | ||
| sD-dimer | TB | 490 | 2.69 | 1.19 | <0.001 |
| CA | 141 | 0.67 | 0.07 | ||
| sFDP | TB | 490 | 9.45 | 0.42 | <0.001 |
| CA | 141 | 7.17 | 0.94 | ||
| sESR | TB | 530 | 46.25 | 1.16 | <0.001 |
| CA | 136 | 29.78 | 2.32 | ||
| sWBC | TB | 545 | 6.48 | 0.11 | <0.001 |
| CA | 155 | 7.70 | 0.24 | ||
| sLYMp | TB | 545 | 19.14 | 0.45 | 0.037 |
| CA | 155 | 20.16 | 0.64 | ||
| sEOSp | TB | 545 | 2.24 | 0.22 | 0.003 |
| CA | 155 | 3.37 | 0.94 | ||
| sMONp | TB | 545 | 10.35 | 0.17 | <0.001 |
| CA | 155 | 7.18 | 0.20 | ||
| sHGB | TB | 545 | 120.09 | 0.84 | 0.037 |
| CA | 155 | 123.27 | 1.55 | ||
| sPLT | TB | 545 | 292.18 | 4.25 | <0.001 |
| CA | 155 | 255.16 | 6.38 | ||
| sNA | TB | 492 | 139.38 | 0.32 | <0.001 |
| CA | 127 | 140.74 | 0.37 | ||
| sCL | TB | 491 | 104.42 | 1.85 | 0.001 |
| CA | 127 | 103.39 | 0.40 | ||
| sALT | TB | 512 | 23.65 | 1.28 | 0.029 |
| CA | 123 | 15.82 | 1.14 | ||
| s | TB | 512 | 42.48 | 2.30 | 0.001 |
| CA | 123 | 29.89 | 2.68 | ||
| sTP | TB | 425 | 69.07 | 1.72 | <0.001 |
| CA | 102 | 64.01 | 0.67 | ||
| sGLO | TB | 423 | 32.46 | 0.87 | <0.001 |
| CA | 102 | 27.26 | 0.73 | ||
| sA/G | TB | 423 | 1.19 | 0.02 | <0.001 |
| CA | 102 | 1.49 | 0.08 | ||
| sTB | TB | 426 | 10.37 | 0.28 | <0.001 |
| CA | 104 | 12.38 | 0.62 | ||
| sTBA | TB | 454 | 4.00 | 0.27 | 0.001 |
| CA | 106 | 2.74 | 0.24 | ||
| sPA | TB | 437 | 148.70 | 3.70 | <0.001 |
| CA | 102 | 193.11 | 7.51 | ||
| sUREA | TB | 495 | 4.69 | 0.70 | <0.001 |
| CA | 127 | 6.75 | 1.89 | ||
| sCRE | TB | 494 | 85.45 | 0.75 | 0.028 |
| CA | 127 | 83.70 | 1.56 | ||
| sCKI | TB | 58 | 6.33 | 0.35 | 0.038 |
| CA | 24 | 14.13 | 5.26 | ||
| sLDH | TB | 61 | 170.62 | 6.02 | 0.024 |
| CA | 24 | 221.54 | 31.01 | ||
| sHsCRP | TB | 301 | 50.30 | 2.67 | <0.001 |
| CA | 70 | 19.25 | 3.20 |
pADA = hydrothorax adenosine dehydrogenase, pAMS = hydrothorax amylase, pCell = hydrothorax cells, pGLU = hydrothorax glucose, pHsCRP = hydrothorax high sensitivity C reactive protein, pMON = hydrothorax monocytes, pTP = hydrothorax total protein, sA/G = blood A/G, sALT = alanine aminotransferase, sCa = serum calcium, sCK = blood creatine kinase, sCKI = blood creatine kinase isoenzyme, sCL = blood chlorine, sCRE = serum creatinine, sD-dimer = blood D-dimer, sEOSp = percentage of eosinophil, sESR = erythrocyte sedimentation rate, sFbg = blood fibrin, sFDP = fibrinogen degradation products, sGLO = globin, sHGB = hemoglobin, sHsCRP = blood high sensitivity C reactive protein, sINR = blood internationalization standardized ratio, sLDH = serum lactate dehydrogenase, sLYMp = lymphocyte percentage, sMONp = percentage of blood monocyte, sNA = blood natrium, sPA = blood prealbumin, sPLT = platelet, sPT = prothrombin time, sPTA = prothrombin activity, sPTR = prothrombin time ratio, sTB = total bilirubin, sTBA = total bile acid, sTP = blood total protein, sTT = blood thrombin time, sUREA = blood urea, sWBC = white blood cell, sγ-GT = blood γ glutamyl transpeptidase.
Figure 2.Blood and pleural effusion clinical indicators (N = 37) with statistical significance of TB and CA. (A) 20 indicators; (B) 17 indicators (mean value with SEM, *P < .05; **P < .01; ***P < .001). CA= tumor, TB = tuberculosis.
Figure 3.ROC analysis of blood and pleural effusion clinical indicators distinguishing TB from CA. (A) pADA ROC curve; (B) pHsCRP ROC curve; (C) sMONp ROC curve; (D) sHsCRP ROC curve; (E) sESR ROC curve; (F) sD-dimer ROC curve (AUC > 0.7). CA= tumor, pADA = hydrothorax adenosine dehydrogenase, pHsCRP = hydrothorax high sensitivity C reactive protein, sD-dimer = blood D-dimer, sESR = erythrocyte sedimentation rate, sHsCRP = blood high sensitivity C reactive protein, sMONp = percentage of blood monocyte, TB = tuberculosis.
ROC analysis of blood and pleural effusion indicators.
| Features | AUC | Std. Error | 95% Confidence Interval | Asymptotic Sig. |
|---|---|---|---|---|
| pADA | 0.90 | 0.015 | 0.87–0.93 | <0.001 |
| pHsCRP | 0.79 | 0.021 | 0.75–0.83 | <0.001 |
| sMONp | 0.75 | 0.02 | 0.71–0.79 | <0.001 |
| sHsCRP | 0.73 | 0.031 | 0.67–0.79 | <0.001 |
| sESR | 0.71 | 0.027 | 0.66–0.76 | <0.001 |
| D-dimer | 0.70 | 0.027 | 0.64–0.75 | <0.001 |
D-dimer = blood D-dimer, pADA = hydrothorax adenosine dehydrogenase, pHsCRP = hydrothorax high sensitivity C reactive protein, sMONp = percentage of blood monocyte, sHsCRP = blood high sensitivity C reactive protein, sESR = erythrocyte sedimentation rate.
Figure 4.PCA analysis of 6 comparable blood and pleural effusion indicators of tuberculosis and tumor. PCA = principal component analysis.
Figure 5.ROC analysis of combined indicators in tuberculosis detection form tumor patients.
Figure 6.ROC analysis of selected indicator pADA in different statuses of patients. (A) pADA ROC curve (male); (B) pADA ROC curve (female); (C) pADA ROC curve (Fever); (D) pADA ROC curve (No fever); (E) pADA ROC curve (age < 25); (F) pADA ROC curve (25 ≤ age < 45); (G) pADA ROC curve (45 ≤ age < 65); (H) pADA ROC curve (age ≥ 65). pADA = hydrothorax adenosine dehydrogenase.